12月2日上午，在"中国药品价格登记系统发布活动"仪式上，国家医保局发布《关于开展药品价格登记 查询服务的公告》，并与北京市人民政府共同启动中国药品价格登记系统（以下简称"中国药登"）。 中国医药、同仁堂、百济神州、康方生物、亿帆医药、罗氏制药、药明巨诺、南京驯鹿、恒瑞医药等多 家知名医药企业现场进行了药品价格登记。 独立于各省级医药采购平台 据悉，中国药品价格登记系统由国家医保局发起建立，国家医保局和北京市人民政府加强合作，委托西 城区国资企业采取社会化运营模式，按照"一地受理、全国共享、全球公开"的经办原则，同步在线上线 下为国内外医药企业提供药品价格登记查询服务。 国家医保局价格招采司负责人介绍，近年来，我国医药产业创新能力显著增强，中国创新药出海，已经 从一个可选项变成了许多药企的必选项和生存发展之道。出海并获得全球市场的认可，是提升公司估 值、证明自身价值、为后续研发"输血"的关键途径。出海不仅仅是卖药，更是在全球生物医药产业链中 占据一席之地，中国药企可以逐步建立国际品牌影响力，吸引全球顶尖人才，融入全球创新网络。 国家医保局价格招采司负责人称，在创新药国际化进程中，面临着传统单一价格体系难以完全 ...

Core Points - The launch of the China Drug Price Registration System aims to facilitate the globalization of Chinese innovative drugs and attract high-quality foreign drugs to the Chinese market, benefiting patients in China [1][4] - The system operates under a "one location acceptance, nationwide sharing, global openness" service mechanism, allowing pharmaceutical companies to independently declare and register drug prices [1][4] - The establishment of this system fills a gap in the national-level drug pricing disclosure framework in China, enhancing the credibility of registered prices compared to provincial systems [5] Group 1: System Overview - The China Drug Price Registration System (China Drug Registration) was officially launched on December 2, providing a platform for drug price registration and inquiry [1] - The system is a collaboration between the National Healthcare Security Administration and the Beijing Municipal Government, operated by a state-owned enterprise under a socialized operation model [1][4] - The registration process allows drug market authorization holders to voluntarily declare prices and is open for public inquiry, ensuring transparency [5] Group 2: Industry Impact - The system is expected to significantly impact the high-quality development of the pharmaceutical industry in China, aligning with the country's goal of building a healthy China and supporting the development of innovative drugs and medical devices [3][4] - By providing a platform for global price registration, the system helps Chinese pharmaceutical companies establish a comprehensive global pricing framework, enhancing the modernization of drug price governance [4][5] - The system's independent operation from provincial procurement platforms allows for a clearer distinction between market prices and negotiated prices under healthcare insurance [4][5]

开展药品登记查询服务 在活动现场，国家医保局正式发布《关于开展药品价格登记查询服务的公告》，并与北京市人民政府共同启动中国药登，委托西城区国资企业采取社会化运 营模式，按照"一地受理、全国共享、全球公开"的经办原则，同步在线上线下为国内外医药企业提供药品价格登记查询服务。 12月2日，由国家医保局与北京市人民政府联合主办的中国药品价格登记系统（以下简称"中国药登"）发布仪式在京举行，9家药企在现场进行首批登记。国 家医保局《关于开展药品价格登记查询服务的公告》同时发布，旨在构建全球化药品价格体系，支持创新药高质量发展，推动中国医药产业更好融入国际竞 争。 中国药登的建立，是国家医保局在《支持创新药高质量发展的若干措施》框架下，全链条支持创新药发展的重要举措之一。中国药登将通过提供规范、透明 的价格信息服务，助力中国药企拓展国际市场，同时吸引更多国际创新药进入中国，最终惠及全球患者。 N. 4 .. PL L A 1 1 1412 7/2 地方 an 123 11 据了解，在国际上对药品实行两套价格机制是通行的做法。一套是公开的市场标价，可查可比；一套是保密的医保支付价，用于结算；医保支付价一般情况 下低于市场 ...

Core Insights - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a net redemption of 2.867 million yuan on December 1, ranking 15th out of 198 in cross-border ETF net outflows [1] - As of December 1, the fund's latest size is 5.56 billion yuan, down from 5.59 billion yuan the previous day, with a net outflow accounting for 0.05% of the previous day's size [1] - Over the past 5 days, the fund faced a net redemption of 4.3125 million yuan, ranking 53rd out of 198 in cross-border ETF net outflows [1] - In the last 10 days, the fund saw a net subscription of 129 million yuan, ranking 34th out of 198 in cross-border ETF net inflows [1] - Over the past 20 days, the fund had a net subscription of 251 million yuan, ranking 36th out of 198 in cross-border ETF net inflows [1] Fund Details - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) was established on March 26, 2025, with an annual management fee of 0.40% and a custody fee of 0.07% [1] - The fund tracks the Hong Kong Stock Connect Innovative Drug Index (987018) [1] - As of December 1, the fund's total shares are 3.865 billion, with a total size of 5.56 billion yuan [1] Liquidity and Performance - As of December 1, the fund's cumulative trading amount over the last 20 trading days is 13.981 billion yuan, with an average daily trading amount of 699 million yuan [2] - The current fund managers are Liu Weilin and Jiao Wenlong, with returns of 43.85% and 63.95% respectively since their management began [2] Top Holdings - The fund's top holdings include: - 百济神州 (10.84%, 314.54 million shares, 589 million yuan) - 康方生物 (10.77%, 454.20 million shares, 586 million yuan) - 信达生物 (10.43%, 644.10 million shares, 567 million yuan) - 中国生物制药 (9.82%, 7184.50 million shares, 534 million yuan) - 石药集团 (7.72%, 4908.40 million shares, 420 million yuan) - 三生制药 (7.41%, 1469.60 million shares, 403 million yuan) - 翰森制药 (5.50%, 908.20 million shares, 299 million yuan) - 科伦博泰生物-B (3.55%, 41.14 million shares, 193 million yuan) - 再鼎医药 (2.79%, 621.62 million shares, 151 million yuan) [2] Comparative Analysis - Other ETFs tracking the Hong Kong Stock Connect Innovative Drug Index include: - 汇添富国证港股通创新药ETF (159570) with a size of 23.978 billion yuan and a recent average daily trading amount of 2.652 billion yuan [2] - 港股创新药ETF (159567) with a size of 8.460 billion yuan and a recent average daily trading amount of 1.457 billion yuan [2] - 南方国证港股通创新药ETF (159297) with a size of 1.459 billion yuan and a recent average daily trading amount of 0.115 billion yuan [2] - 鹏华国证港股通创新药ETF (159286) with a size of 0.607 billion yuan and a recent average daily trading amount of 0.088 billion yuan [2]

恒生银行高开低走后探底回升，截至收盘上涨0.36%。其中重庆农村商业银行大涨3.18%，青岛银行上 涨2.27%，重庆银行、渣打银行、浙商银行等近10只个股涨幅在1%上方；光大银行逆势大跌3.16%，邮 储银行下跌2.55%。 恒生医疗相对偏弱，深V反转后小涨0.06%。其中京东健康大涨3.93%，药明生物、三生制药、药明康德 等股涨幅均在1%上方；康方生物、中国生物、石药集团等股逆势收跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生指数冲高回落后全天维持在中轴上方窄幅盘整，截止收盘上涨0.67%。互联网涨幅居前，科技、银 行紧随其后；医疗、大消费相对偏弱。 互联网小幅低开后直线拉升，随后全天维持在中轴上方窄幅盘整，截止收盘上涨0.75%。其中网易大涨 3.93%，阿里巴巴上涨2.24%，地平线机器人、百度集团、腾讯控股等多股涨幅均在1%上方。 ...

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The retail pharmacy sector is expected to benefit from the recent surge in flu cases, with a significant increase in demand for antiviral medications and symptomatic treatments [5][15] - The retail pharmacy industry is anticipated to undergo accelerated consolidation, with smaller pharmacies exiting the market, leading to increased customer traffic for leading players [6][34] - The implementation of drug traceability codes is expected to enhance industry compliance and further increase market concentration [6][18] Summary by Sections Industry Overview - The closing index for the industry is 8430.03, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - The A-share pharmaceutical sector rose by 2.67% from November 24 to November 28, 2025, outperforming the CSI 300 index by 1.03 percentage points [19][35] - The Hang Seng Healthcare Index increased by 3.64%, outperforming the Hang Seng Index by 1.1 percentage points [35][36] Industry Insights and Investment Recommendations 1. **Innovative Drugs**: The long-term trend for innovative drugs is positive, with China's capabilities in global competition strengthening [9][21] - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and others [10][22] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3 [10][26] - Recommended stocks include Mindray, Aohua Endoscopy, and others [27][28] 3. **Traditional Chinese Medicine**: The sector is under pressure but is expected to benefit from basic drug policies and innovation [31][32] - Recommended stocks include Zhaoke Ophthalmology, Fangsheng Pharmaceutical, and others [31][32] 4. **Retail Pharmacy**: The retail pharmacy sector is expected to see increased concentration, with leading pharmacies benefiting from enhanced service capabilities and supply chain management [6][34] - Recommended stocks include Yifeng Pharmacy and Dazhong Pharmacy [7][34]

Investment Rating - The report maintains an "Outperform" rating for the industry [2]. Core Insights - The third-generation EGFR TKI has become the first-line standard therapy for advanced EGFR mutation NSCLC, significantly extending median progression-free survival (mPFS) to 18.9-22.1 months compared to earlier generations [4][24]. - The domestic EGFR TKI market is expected to exceed 20 billion CNY in 2024, with third-generation EGFR TKIs accounting for 88% of the market share [4][30]. - There is an urgent need to address resistance mechanisms following third-generation EGFR TKI treatment, with ongoing exploration of fourth-generation TKIs, bispecific antibodies, and antibody-drug conjugates (ADCs) [5][32]. Summary by Sections 1. High Incidence of Lung Cancer in China - Lung cancer is the most common malignant tumor globally, with approximately 2.6 million new cases expected in 2024, including about 1.15 million in China [8]. - Non-small cell lung cancer (NSCLC) accounts for around 85% of lung cancer cases, with adenocarcinoma and squamous cell carcinoma being the most prevalent subtypes [8]. 2. Third-Generation EGFR TKI as First-Line Therapy - The third-generation EGFR TKI has established itself as the first-line treatment for advanced EGFR mutation NSCLC, with significant improvements in mPFS compared to first and second generations [4][16][24]. - The report highlights the efficacy of third-generation TKIs in overcoming common mutations and their favorable safety profile [4][24]. 3. Exploration of Resistance Mechanisms - The report discusses the complexity of resistance mechanisms to third-generation EGFR TKIs, including both EGFR-dependent and independent pathways [5][32]. - Current research focuses on developing fourth-generation TKIs targeting specific mutations and exploring combination therapies with bispecific antibodies and ADCs [5][32][39]. 4. Investment Recommendations - The report emphasizes the growth potential of third-generation EGFR TKIs and suggests monitoring companies like Hansoh Pharma and Eli Lilly for market penetration and sales growth [51]. - It also highlights the progress of ADCs and bispecific antibodies in clinical trials, indicating a robust pipeline for future treatments [51][52].

Group 1: Federal Reserve and Market Expectations - Goldman Sachs indicates that the Federal Reserve is expected to lower interest rates during the December 9-10 meeting, with a nearly certain probability of a 25 basis point cut at around 85%-86% [1] Group 2: Company Developments - Baillie Gifford's subsidiary SystImmune received a $250 million milestone payment from Bristol-Myers Squibb related to the global strategic collaboration agreement, with potential for up to $2.5 billion in near-term or contingent payments and an additional $7.1 billion upon achieving specific development, registration, and sales milestones [1] - Innovent Biologics announced that its self-developed drug, Xinmeiyue® (Pikankizumab injection), has been approved by the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis in adult patients, marking a significant advancement in domestic precision treatment for psoriasis [1] Group 3: Market Performance and Trends - The Hong Kong Stock Connect Innovation Drug ETF (159570) experienced a decline of over 1% for two consecutive days, with a trading volume exceeding 1 billion yuan, and a net inflow of 80 million yuan during the day [3] - As of November 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) exceeded 24 billion yuan, leading its peers in the same category [3] Group 4: Upcoming Events and Industry Catalysts - The results of the drug catalog negotiation conducted by the Medical Insurance Bureau are expected to be released in the first weekend of December, with a focus on the inclusion of domestic biological innovative drugs for skin diseases in the medical insurance [4] - The American Society of Hematology (ASH) conference is set to take place from December 6-9, where multiple differentiated hematology products will have data disclosed, with a focus on companies like BeiGene, Innovent Biologics, and others [4] Group 5: Company Stock Performance - The weighted stocks of the Hong Kong Stock Connect Innovation Drug ETF (159570) showed mixed performance, with major stocks like Rongchang Bio down over 5%, while Innovent Biologics and Hansoh Pharmaceutical saw slight increases [1][2]

Core Insights - A paradigm shift in cancer treatment is underway, driven by combination therapies rather than single-agent treatments, as highlighted by Pfizer's strategy to focus on ADC combinations instead of direct comparisons with standard treatments or placebos [1][20] - Combination therapies are emerging as a significant trend in innovative drug development, addressing the limitations of single-agent therapies, such as low response rates and inevitable resistance [1][2] Group 1: Advantages of Combination Therapies - Combination therapies enhance efficacy and response rates, delay the onset of resistance, and maintain durable anti-tumor activity, significantly improving clinical value [2][3] - A notable example is the combination of Osimertinib with chemotherapy, which significantly extended the overall survival (OS) of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) [2] Group 2: Market Dynamics and Competitive Landscape - The pharmaceutical industry is experiencing a "combination competition" era, where various combination strategies are being employed across different disease areas, leading to synergistic effects [7][20] - AstraZeneca's Osimertinib, despite being a top-selling drug, faces challenges from competitors and is implementing a comprehensive combination strategy to maintain its market position [5][6] Group 3: Ongoing Research and Development - Numerous clinical trials are underway exploring various combination therapies, including PD-(L)1 inhibitors with chemotherapy and other agents, indicating a robust pipeline in the oncology sector [14][19] - The exploration of combination therapies is not limited to solid tumors; significant advancements are also being made in hematological malignancies, showcasing the broad applicability of this approach [10][12] Group 4: Future Directions - The current landscape of drug development suggests that combination therapies will reshape the research and commercial ecosystem of the pharmaceutical industry, emphasizing the need for companies to adapt to this trend to remain competitive [20]

Core Viewpoint - The pharmaceutical sector has shown a volatile upward trend since early 2025, with a brief correction highlighting its cost-effectiveness, despite current valuations being at historical medians since 2010, indicating room for market capitalization growth [1] Group 1: Innovative Drug Industry Chain - Emphasis on innovation and the importance of high-quality domestic clinical data to catalyze opportunities for profit recovery in the industry [2] - Domestic assets are gaining global recognition, with strong demand for new product iterations and favorable conditions for domestic new drugs to enter international markets [2] - The dual-antibody market (PD-(L)1/VEGF) is experiencing increasing market heat and transaction value, with potential for synergistic effects alongside ADC mechanisms [2] Group 2: New Therapeutic Approaches - High demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to maintain rapid growth, with a recovery in outsourcing demand anticipated during the overseas interest rate decline [3] - The domestic market is poised for a recovery in demand and primary market conditions, with a potential for rapid profit recovery as supply-side capacity reduction slows [3] Group 3: Non-Pharmaceutical Sector - Medical devices are showing signs of a turning point, with growth stabilizing for certain companies and a recovery in bidding processes expected to impact 2026 performance positively [4] - The traditional Chinese medicine sector is likely to see continued adjustments in essential drug catalogs, with opportunities arising from price declines in raw materials [4] - Retail pharmacies are undergoing accelerated consolidation, with leading pharmacies optimizing store structures to alleviate profit pressures, leading to expected profit margin improvements in 2026 [4]